Close Menu

NEW YORK (360Dx) – Hennigsdorf, Germany-based Sphingotec said today that it recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of biomarkers that could improve the diagnosis of certain disease states, including kidney disease, breast cancer, sepsis, and cardiovascular disease.

Under the agreement, for research and potential routine clinical use, Mayo Clinic will evaluate proenkephalin (penKid), a blood-based biomarker that provides information on the current status of kidney function, and three other biomarkers, Sphingotec said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.